{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khalighi M"],"funding":["NCATS NIH HHS"],"pagination":["204-209"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9329177"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(2)"],"pubmed_abstract":["<h4>Purpose</h4>The aim of this study is to compare the patient-reported bleeding outcomes and complication rates with the use of the 52-mg levonorgestrel-releasing intrauterine system (52-LNG-IUS) for treatment of heavy menstrual bleeding (HMB) among adolescents with and without a diagnosed inherited bleeding disorder (BD) within the first 12 months after insertion.<h4>Methods</h4>Retrospective chart review was conducted of adolescents ages 14-21 years, with and without an inherited BD, who underwent 52-LNG-IUS insertion between September 2013 and February 2020 for the treatment of HMB.<h4>Results</h4>One hundred forty-four 52-LNG-IUS insertions among 139 subjects were evaluated. Fifty-nine (41%) of these were among adolescents with a diagnosed inherited BD, and 85 (59%) were among those "],"journal":["The Journal of adolescent health : official publication of the Society for Adolescent Medicine"],"pubmed_title":["Does a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study."],"pmcid":["PMC9329177"],"funding_grant_id":["UL1 TR001855"],"pubmed_authors":["Durazo-Arvizu RA","Kouides PA","Khalighi M","Adeyemi-Fowode OA","Dersch CM","Wheeler AP","Haley K","Weyand AC","Borzutzky C","Baldwin MK"],"additional_accession":[]},"is_claimable":false,"name":"Does a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study.","description":"<h4>Purpose</h4>The aim of this study is to compare the patient-reported bleeding outcomes and complication rates with the use of the 52-mg levonorgestrel-releasing intrauterine system (52-LNG-IUS) for treatment of heavy menstrual bleeding (HMB) among adolescents with and without a diagnosed inherited bleeding disorder (BD) within the first 12 months after insertion.<h4>Methods</h4>Retrospective chart review was conducted of adolescents ages 14-21 years, with and without an inherited BD, who underwent 52-LNG-IUS insertion between September 2013 and February 2020 for the treatment of HMB.<h4>Results</h4>One hundred forty-four 52-LNG-IUS insertions among 139 subjects were evaluated. Fifty-nine (41%) of these were among adolescents with a diagnosed inherited BD, and 85 (59%) were among those ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T20:07:06.593Z","creation":"2025-04-04T20:07:06.593Z"},"accession":"S-EPMC9329177","cross_references":{"pubmed":["35430143"],"doi":["10.1016/j.jadohealth.2022.02.018"]}}